Speciality: Hematology
Description:
A warm welcome to all the medical professionals in this session, focusing on Ferric Maltol as a New Treatment Option- A Further Discussion on a New Perspective on Iron Deficiency Anemia (IDA). This discussion will build upon previous insights, offering a fresh perspective on how ferric maltol's unique properties are changing the clinical approach to IDA. The key new perspective lies in its ability to circumvent the common limitations of traditional oral iron supplements, particularly in patients with chronic inflammatory conditions.
A major challenge with conventional oral iron salts is their poor absorption and high incidence of gastrointestinal side effects, which is often exacerbated by inflammation. Ferric maltol offers a new paradigm by maintaining a stable and soluble complex of iron (Fe³⁺) and maltol, which prevents the formation of free iron in the gut. This minimizes irritation and oxidative stress, leading to superior gastrointestinal tolerability. This is crucial for patients with conditions like Inflammatory Bowel Disease (IBD), where traditional iron can worsen symptoms.
Therefore, get a comprehensive understanding of this new perspective on IDA management. This session will provide valuable insights into how ferric maltol's unique mechanism translates into better patient outcomes and adherence, particularly for those with a history of intolerance or non-response to conventional oral iron. Absorb the shared knowledge and follow Hidoc for more such indispensable sessions that keep you at the forefront of medical advancements.
See More Webinars @ Hidoc Webinars
1.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
2.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
3.
Nearly 4 million lung cancer deaths averted and 76 million years of life gained due to tobacco control in US
4.
Targeted Combination Shows Promise in Metastatic Kidney Cancer
5.
Through Consolidation Durvalumab, Limited-Stage SCLC Receives a New Standard of Care.
1.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
2.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
3.
Late Effects of Immunotherapy in Chronic Melanoma Survivorship with Repurposed Drugs
4.
Beyond the Human Eye: How AI Is Redefining Brain Cancer Diagnosis Through Advanced Imaging
5.
The Converging Frontiers of Radiation Oncology and Systemic Therapies by 2025
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VI
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
5.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation